Timely and relevant thoracic oncology news brought to you by the only global association dedicated to the multidisciplinary study of lung cancer.

Timely and relevant thoracic oncology news brought to you by the only global association dedicated to the multidisciplinary study of lung cancer.

Search results for: “patient perspective”

  • ADAURA: Data is Only Part of the Story

    ADAURA: Data is Only Part of the Story

    By

    Early Stage

    Patient Research Advocate (PRA) and 12-year survivor, Jill Feldman, discusses scientific and humanistic concerns regarding the ADAURA trials current data on disease-free progression in NSCLC. As a patient, osimertinib has given Ms. Feldman the hope that she has not had since her diagnosis. As a PRA, there are concerns about the lack of information about…

  • Targeting KRAS in Lung Cancer: The Past, Present, and Future 

    Targeting KRAS in Lung Cancer: The Past, Present, and Future 

    By

    Targeted Therapies

    Although RAS mutations constitute some of the most common genetic alterations in patients with adenocarcinomas, efforts to target the RAS oncoprotein have not proven fruitful, not only in NSCLC but across all cancers. In fact, researchers have been searching for an effective RAS inhibitor for more than 3 decades, leading many to believe that RAS…

  • Sotorasib Shows Early Activity Against KRAS G12C Mutant NSCLC

    Sotorasib Shows Early Activity Against KRAS G12C Mutant NSCLC

    By

    Big News

    The first-in-class KRAS G12C inhibitor sotorasib has demonstrated early, deep, and durable responses in the treatment of advanced NSCLC with KRAS G12C mutations, according to results from the registrational phase II CodeBreaK 100 trial. “Breakthrough therapy designation was granted by U.S. Food and Drug Administration (FDA), and I am pleased to report that regulatory filings…

  • Immunohistochemistry’s Important Role in Diagnosis of Thoracic Cancers Explained in a New Atlas

    Immunohistochemistry’s Important Role in Diagnosis of Thoracic Cancers Explained in a New Atlas

    By

    Keith M. Kerr, BSc, MB, ChB, et al.
    Behind the Scenes, WCLC 2020 Archive

    The latest in the series of diagnostic Atlases has been published by the IASLC and its Pathology Committee. Following the highly successful editions on ALK, EGFR, ROS1 and PD-L1, this latest Atlas takes a comprehensive look at diagnostic immunohistochemistry (IHC) and its role in thoracic pathology. The editorial team of Drs. Yasushi Yatabe, Alain Borczuk,…

  • Program Trains Patient Research Advocates to be STARS

    Program Trains Patient Research Advocates to be STARS

    By

    Patient Advocacy, WCLC 2020 Archive

    What does it take to become a star in any setting? Passion, knowledge, and drive. When it comes to understanding the science of lung cancer, sometimes the experts are the patients themselves. The IASLC is looking for patients and caregivers who want to learn about lung cancer science and research, as well as develop their…

  • Enhancing Your WCLC Experience with Twitter

    Enhancing Your WCLC Experience with Twitter

    By

    Patient Advocacy, WCLC 2020 Archive

    Even those who are unfamiliar with social media platforms can find Twitter to be an easy way to discuss research and collaborate with colleagues. If you do not already have a Twitter account, you should consider setting one up now! During a virtual conference, Twitter is the best possible replacement for the hallway conversations that…

  • Finding the Benefits of the Virtual World: A Conversation with Dr. Heather Wakelee

    Finding the Benefits of the Virtual World: A Conversation with Dr. Heather Wakelee

    By

    Behind the Scenes, WCLC 2020 Archive

    Heather Wakelee, MD, is the President-Elect of the IASLC and will assume presidential responsibilities at the 2021 WCLC in September. She is the Chief of the Division of Oncology at Stanford University and Deputy Director of the Stanford Cancer Institute. She is also the principal investigator of numerous clinical trials and lead investigator for the…

  • Interim Chief Scientific Officer Dr. Giorgio Scagliotti Brings Vast IASLC Knowledge to Role

    Interim Chief Scientific Officer Dr. Giorgio Scagliotti Brings Vast IASLC Knowledge to Role

    By

    Behind the Scenes, WCLC 2020 Archive

    With a long history in leadership positions at the IASLC, Dr. Scagliotti is fully prepared to help guide the society’s scientific projects through a transition period. Dr. Scagliotti, is professor of medical oncology at the University of Turin School of Medicine, Italy, where he is also a member of the administrative board. He is also…

  • Revised U.S. Food and Drug Administration Trial Eligibility Guidance: A Major Step Toward Transforming Lung Cancer Clinical Trials

    Revised U.S. Food and Drug Administration Trial Eligibility Guidance: A Major Step Toward Transforming Lung Cancer Clinical Trials

    By

    David E. Gerber, MD, et al.
    Clinical Trial Design

    By now, investigators, sponsors, clinicians, and patients are widely aware of the crisis facing cancer clinical trials. With scientific discoveries occurring more rapidly than ever, there is a growing need to bring novel therapies to patients as efficiently as possible. Yet, in the United States, fewer than 3% of adults with cancer enroll in clinical…

  • FDA’s Project Patient Voice Launched to Provide Data on PROs

    FDA’s Project Patient Voice Launched to Provide Data on PROs

    By

    Patient Advocacy

    In 2020 the U.S. Food and Drug Administration (FDA) launched Project Patient Voice, an online platform for patients and caregivers along with their health care providers to look at patient-reported symptom data from cancer clinical trials.  This new website, how it functions, and how it might be improved was discussed in July at the FDA-ASCO…

View ILCN Archives

Provider Resources

Popular Articles